Preferred Label : ozanimod;
UNII : Z80293URPV;
Origin ID : C000607776;
UMLS CUI : C4278675;
ATC code(s)
- Currated CISMeF NLP mapping
- Manual BTNT mappings - CISMeF
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3410991/fr/zeposia-ozanimod-sclerose-en-plaques
2023
false
false
false
France
administration, oral
ozanimod
withdrawing treatment
Medication set-up education, guidance, and counseling (procedure)
evaluation of the transparency committee
multiple sclerosis, relapsing-remitting
ozanimod
---
https://ansm.sante.fr/tableau-marr/ozanimod
2022
false
false
false
France
French
risk management
ozanimod
ozanimod
guidelines for drug use
Product containing precisely ozanimod (as ozanimod hydrochloride) 230 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 460 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 920 microgram/1
each conventional release oral capsule (clinical drug)
ozanimod
administration, oral
continuity of patient care
patients guideline
pregnancy
ozanimod
---
https://www.has-sante.fr/jcms/p_3352182/fr/zeposia-ozanimod-chlorhydrate-d-rectocolite-hemorragique-rch
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
Product containing precisely ozanimod (as ozanimod hydrochloride) 920 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 460 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 230 microgram/1
each conventional release oral capsule (clinical drug)
Ozanimod Hydrochloride
ozanimod
adult
evaluation of the transparency committee
colitis, ulcerative
ozanimod
---
https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ozanimod
ozanimod
ozanimod
adult
multiple sclerosis, relapsing-remitting
administration, oral
Sphingosine-1-Phosphate receptors
product surveillance, postmarketing
aged
drug interactions
contraception
pregnancy
breast feeding
drug evaluation, preclinical
Product containing precisely ozanimod (as ozanimod hydrochloride) 460 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 230 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 920 microgram/1
each conventional release oral capsule (clinical drug)
receptors, lysosphingolipid
indans
oxadiazoles
indans
oxadiazoles
---
https://www.has-sante.fr/jcms/p_3226174/fr/zeposia
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
ozanimod
ozanimod
ozanimod
adult
multiple sclerosis, relapsing-remitting
administration, oral
Sphingosine-1-Phosphate receptors
Product containing precisely ozanimod (as ozanimod hydrochloride) 230 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 460 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 920 microgram/1
each conventional release oral capsule (clinical drug)
evaluation of the transparency committee
receptors, lysosphingolipid
indans
oxadiazoles
indans
oxadiazoles
---
